Krystal Biotech, Inc. (KRYS) stock
KRYSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 2, 2026Score 11/3042% above fair value
$305.23−0.45 (-0.15%)
Close on Nov 13, 2026Market cap $9.03BP/E 41.4Yield –
Krystal Biotech ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Krystal Biotech's ebitda for the twelve months ending Sep 30, 2023 was -$143.98M. For fiscal 2022 it was -$141.14M.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | -$141.14M | – |
| FY2021 | Dec 31, 2021 | -$65.51M | – |
| FY2020 | Dec 31, 2020 | -$31.15M | – |
| FY2019 | Dec 31, 2019 | -$20.99M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2023 | Sep 30, 2023 | -$25.17M | – |
| Q2 FY2023 | Jun 30, 2023 | -$37.01M | – |
| Q1 FY2023 | Mar 31, 2023 | -$48.12M | – |
| Q4 FY2022 | Dec 31, 2022 | -$33.68M | – |
| Q3 FY2022 | Sep 30, 2022 | -$30.48M | – |
| Q2 FY2022 | Jun 30, 2022 | -$27.78M | – |
| Q1 FY2022 | Mar 31, 2022 | -$49.21M | – |
| Q4 FY2021 | Dec 31, 2021 | -$21.09M | – |
| Q3 FY2021 | Sep 30, 2021 | -$14.87M | – |
| Q2 FY2021 | Jun 30, 2021 | -$15.73M | – |
| Q1 FY2021 | Mar 31, 2021 | -$13.82M | – |
| Q4 FY2020 | Dec 31, 2020 | -$9.93M | – |
| Q3 FY2020 | Sep 30, 2020 | -$9.20M | – |
| Q2 FY2020 | Jun 30, 2020 | -$6.48M | – |
| Q1 FY2020 | Mar 31, 2020 | -$5.53M | – |
| Q4 FY2019 | Dec 31, 2019 | -$5.82M | – |
| Q3 FY2019 | Sep 30, 2019 | -$5.04M | – |
See a number that looks wrong?